Does the GCKR rs1260326 (P446L) variant raise plasma triglycerides?

The GCKR rs1260326 (P446L) variant is a well-established genetic determinant of elevated plasma triglycerides, operating through a specific alteration in hepatic glucose metabolism and lipid synthesis.

Clinical and effectiveness evidence

Large-scale genome-wide association studies (GWAS) and cohort studies consistently link the rs1260326 variant to higher circulating triglycerides.

• Population data: The association has been replicated in diverse populations, including French, Chinese, and multi-ancestry cohorts. In the prospective DESIR study, each copy of the minor T-allele was associated with a 3.41% increase in serum triglycerides.
• VLDL levels: Clinical evidence confirms that the rise in triglycerides is primarily driven by an increase in very-low-density lipoprotein (VLDL) particles, the major carrier of endogenous triglycerides in the blood.

Mechanistic explanations

The variant alters the function of the glucokinase regulatory protein (GKRP), which normally acts as a metabolic switch in the liver.

• Glucokinase activity: The P446L substitution reduces the binding affinity of GKRP for glucokinase (GCK), the enzyme responsible for the first step of glucose metabolism in the liver. This impairs the ability of GKRP to sequester GCK in the nucleus during fasting and reduces its sensitivity to inhibitory signals like fructose-6-phosphate.
• De novo lipogenesis (DNL): The resulting increase in cytosolic GCK activity enhances hepatic glucose uptake and glycolytic flux. This metabolic shift activates transcriptional pathways, such as SREBP-1c, which upregulate key lipogenic enzymes (e.g., FASN and ACC), leading to increased de novo lipogenesis.
• VLDL secretion: Excess lipids produced through DNL are packaged into VLDL particles. Evidence from P446L knock-in mouse models confirms that this increased lipogenic flux directly results in higher VLDL secretion and elevated plasma triglycerides.

Bottom line

The GCKR rs1260326 (P446L) variant is strongly supported as a cause of higher triglycerides. It functions by increasing hepatic glucokinase activity, which drives de novo lipogenesis and subsequent VLDL production.